We are live on ! Find out more
LOAMS

Lombard Odier Asset Management (Switzerland) Portfolio holdings

AUM $2.63B
1-Year Est. Return 31.52%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+31.52%
3 Year Est. Return
+98.77%
5 Year Est. Return
+107.98%
10 Year Est. Return
+494.97%
AUM
$1.27B
AUM Growth
-$291M
Cap. Flow
-$139M
Cap. Flow %
-10.93%
Top 10 Hldgs %
24.84%
Holding
415
New
40
Increased
54
Reduced
57
Closed
258

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$34.3M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$24.4M
3
INCY icon
Incyte
INCY
+$24.2M
4
ELS icon
Equity Lifestyle Properties
ELS
+$23.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$22.7M

Top Sells

Rank Stock Value
1
PHM icon
Pultegroup
PHM
+$28.6M
2
BIIB icon
Biogen
BIIB
+$24.6M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$24.1M
4
ABT icon
Abbott
ABT
+$16.3M
5
POOL icon
Pool Corp
POOL
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 56.62%
2 Financials 13.8%
3 Consumer Discretionary 12.01%
4 Technology 6.24%
5 Energy 3.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
51
Natera
NTRA
$45.5B
$8.09M 0.63%
198,824
-34,293
-15% -$2.06M
EDIT icon
52
Editas Medicine
EDIT
$436M
$7.25M 0.57%
380,963
+67,641
+22% +$1.26M
ITUB icon
53
Itaú Unibanco
ITUB
$81.6B
$7.15M 0.56%
+1,419,196
New +$5.98M
IOVA icon
54
Iovance Biotherapeutics
IOVA
$3.05B
$6.86M 0.54%
412,262
-537,622
-57% -$8.31M
NVTA
55
DELISTED
Invitae Corporation
NVTA
$6.76M 0.53%
847,825
+57,429
+7% +$578K
FATE icon
56
Fate Therapeutics
FATE
$317M
$6.64M 0.52%
171,325
-100,686
-37% -$3.9M
QTRX icon
57
Quanterix
QTRX
$139M
$6.38M 0.5%
218,547
-50,515
-19% -$1.54M
TXG icon
58
10x Genomics
TXG
$7.52B
$6.11M 0.48%
80,276
-75,676
-49% -$6.62M
NVDA icon
59
NVIDIA
NVDA
$5.43T
$5.77M 0.45%
211,530
+31,840
+18% +$799K
NTLA icon
60
Intellia Therapeutics
NTLA
$1.69B
$5.75M 0.45%
79,089
-34,222
-30% -$2.9M
KPTI icon
61
Karyopharm Therapeutics
KPTI
$46M
$5.72M 0.45%
51,737
-58,799
-53% -$7.33M
SGMO
62
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5M 0.39%
860,702
-679,292
-44% -$4.04M
HTHT icon
63
Huazhu Hotels Group
HTHT
$12.7B
$4.84M 0.38%
+146,828
New +$5.44M
ALLO icon
64
Allogene Therapeutics
ALLO
$714M
$4.57M 0.36%
501,219
-494,897
-50% -$5.15M
GTHX
65
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$4.12M 0.32%
542,183
-507,764
-48% -$4.82M
META icon
66
Meta Platforms (Facebook)
META
$1.47T
$4.02M 0.32%
18,086
+820
+5% +$205K
NKE icon
67
Nike
NKE
$60.1B
$3.8M 0.3%
28,213
+2,362
+9% +$332K
PEP icon
68
PepsiCo
PEP
$189B
$3.78M 0.3%
22,573
+9,646
+75% +$1.62M
KURA icon
69
Kura Oncology
KURA
$882M
$3.77M 0.3%
234,372
+15,875
+7% +$229K
DHR icon
70
Danaher
DHR
$145B
$3.61M 0.28%
13,892
+10,729
+339% +$2.69M
PG icon
71
Procter & Gamble
PG
$335B
$3.59M 0.28%
23,479
+5,891
+33% +$922K
CRM icon
72
Salesforce
CRM
$158B
$3.44M 0.27%
16,185
+677
+4% +$146K
KO icon
73
Coca-Cola
KO
$373B
$3.29M 0.26%
53,063
+22,208
+72% +$1.35M
STRO icon
74
Sutro Biopharma
STRO
$353M
$3.21M 0.25%
39,102
-13,742
-26% -$1.31M
MRTX
75
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.21M 0.25%
39,092
-82,644
-68% -$8.45M
1 2
3
4 5

Similar funds

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
CCM
Cerberus Capital Management New York $2.65B AUM 20.18% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
MAMU
Marathon Asset Management (UK) London, United Kingdom $2.61B AUM 27.14% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s Q1 2022 Portfolio in Review

As of Q1 2022, Lombard Odier Asset Management (Switzerland) held 415 positions worth $1.27B, down 19% from $1.57B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Lombard Odier Asset Management (Switzerland) withdrew a net $139M in Q1 2022, closing 258 positions and reducing 57 holdings. Its most notable exit was Pultegroup, an estimated $28.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 53% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Lombard Odier Asset Management (Switzerland) opened a new position in BioMarin Pharmaceuticals worth $22.5M.

  • Lombard Odier Asset Management (Switzerland)'s largest Q1 2022 buy was BioMarin Pharmaceuticals: 291,870 shares worth $22.5M.
  • Lombard Odier Asset Management (Switzerland) added most to CVS Health in Q1 2022, an estimated $34.3M increase.
  • Lombard Odier Asset Management (Switzerland)'s biggest Q1 2022 reduction was Abbott, cutting an estimated $16.3M.
  • Lombard Odier Asset Management (Switzerland) fully exited Pultegroup in Q1 2022, selling an estimated $28.6M.
  • Lombard Odier Asset Management (Switzerland)'s ten largest holdings make up 25% of its $1.27B portfolio in Q1 2022.
  • Lombard Odier Asset Management (Switzerland) opened 40 new positions and closed 258 in Q1 2022.
  • Lombard Odier Asset Management (Switzerland)'s portfolio value fell 19% quarter-over-quarter to $1.27B.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q1 2022, filed 16 May 2022.